Saturday, 20 June 2020

Microbial cyborgs: Bacteria supplying power



One day "microbial cyborgs" might be used in fuel cells, biosensors, or bioreactors. Scientists of Karlsruhe Institute of Technology (KIT) have created the necessary prerequisite by developing a programmable, biohybrid system consisting of a nanocomposite and the Shewanella oneidensis bacterium that produces electrons. The material serves as a scaffold for the bacteria and, at the same time, conducts the microbially produced current.

The bacterium Shewanella oneidensis belongs to the so-called exoelectrogenic bacteria. These bacteria can produce electrons in the metabolic process and transport them to the cell's exterior. However, use of this type of electricity has always been limited by the restricted interaction of organisms and electrode. Contrary to conventional batteries, the material of this "organic battery" does not only have to conduct electrons to an electrode, but also to optimally connect as many bacteria as possible to this electrode. So far, conductive materials in which bacteria can be embedded have been inefficient or it has been impossible to control the electric current.

Researchers have succeeded in developing a nanocomposite that supports the growth of exoelectrogenic bacteria and, at the same time, conducts current in a controlled way. "We produced a porous hydrogel that consists of carbon nanotubes and silica nanoparticles interwoven by DNA strands," Niemeyer says. Then, the group added the bacterium Shewanella oneidensis and a liquid nutrient medium to the scaffold. And this combination of materials and microbes worked. "Cultivation of Shewanella oneidensis in conductive materials demonstrates that exoelectrogenic bacteria settle on the scaffold, while other bacteria, such as Escherichia coli, remain on the surface of the matrix," microbiologist Professor Johannes Gescher explains. In addition, the team proved that electron flow increased with an increasing number of bacterial cells settling on the conductive, synthetic matrix. This biohybrid composite remained stable for several days and exhibited electrochemical activity, which confirms that the composite can efficiently conduct electrons produced by the bacteria to an electrode.


Such a system does not only have to be conductive, it also must be able to control the process. This was achieved in the experiment: To switch off the current, the researchers added an enzyme that cuts the DNA strands, as a result of which the composite is decomposed.

See:

Yong Hu, David Rehnlund, Edina Klein, Johannes Gescher, Christof M. Niemeyer. Cultivation of Exoelectrogenic Bacteria in Conductive DNA Nanocomposite Hydrogels Yields a Programmable Biohybrid Materials System. ACS Applied Materials & Interfaces, 2020; 12 (13): 14806 DOI: 10.1021/acsami.9b22116

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Friday, 19 June 2020

Terrestrial bacteria can grow on nutrients from space



For this study, four non-fastidious environment-derived bacterial species with pathogenic features were selected, including Klebsiella pneumoniae and Pseudomonas aeruginosa. A minimal 'diet' based on nitrogen, phosphorus, sulphur, iron and water to which carbohydrates found in carbonaceous meteorites were added was made to determine whether extraterrestrial survival and growth were possible. The four bacterial species were shown to survive and multiply on this minimal 'diet'.

In follow-up experiments, the team of researchers observed that the adaptation of bacteria, especially in the case of K. pneumoniae, caused changes in the cell membrane -- the shell of the cell -- as a result of which the immune system reacted more strongly to the bacteria. In short, the bacteria become more immunogenic. Research in cell culture, but also in mice, showed that the bacteria survive on extra-terrestrial nutrients and become less virulent as a result of this necessary adaptation. At the same time, this research shows that bacteria can survive under these conditions, which means that the risk of infection among space travellers remains, precisely because -- as other researchers have shown -- a space journey has negative effects on the functioning of the immune system, making astronauts more susceptible to infections.


See:

Jorge Domínguez-Andrés, Marc Eleveld, Georgios Renieris, Thomas J. Boltje, Rob J. Mesman, Laura van Niftrik, Sam J. Moons, Petra Rettberg, Jos W.M. van der Meer, Evangelos J. Giamarellos-Bourboulis, Huub J.M. Op den Camp, Marien I. de Jonge, Mihai G. Netea. Growth on Carbohydrates from Carbonaceous Meteorites Alters the Immunogenicity of Environment-Derived Bacterial Pathogens. Astrobiology, 2020; DOI: 10.1089/ast.2019.2173

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Thursday, 18 June 2020

Evolution of coronavirus SARS-CoV-2


A team of scientists studying the origin of SARS-CoV-2, the virus that has caused the COVID-19 pandemic, found that it was especially well-suited to jump from animals to humans by shapeshifting as it gained the ability to infect human cells.

Conducting a genetic analysis, researchers from Duke University, Los Alamos National Laboratory, the University of Texas at El Paso and New York University confirmed that the closest relative of the virus was a coronavirus that infects bats. But that virus's ability to infect humans was gained through exchanging a critical gene fragment from a coronavirus that infects a scaly mammal called a pangolin, which made it possible for the virus to infect humans.

The researchers report that this jump from species-to-species was the result of the virus's ability to bind to host cells through alterations in its genetic material. By analogy, it is as if the virus retooled the key that enables it to unlock a host cell's door -- in this case a human cell. In the case of SARS-CoV-2, the "key" is a spike protein found on the surface of the virus. Coronaviruses use this protein to attach to cells and infect them.

Very much like the original SARS that jumped from bats to civets, or MERS that went from bats to dromedary camels, and then to humans, the progenitor of this pandemic coronavirus underwent evolutionary changes in its genetic material that enabled it to eventually infect humans.

The researchers said tracing the virus's evolutionary pathway will help deter future pandemics arising from the virus and possibly guide vaccine research. The researchers found that typical pangolin coronaviruses are too different from SARS-CoV-2 for them to have directly caused the human pandemic.


See:

Xiaojun Li, Elena E. Giorgi, Manukumar Honnayakanahalli Marichannegowda, Brian Foley, Chuan Xiao, Xiang-Peng Kong, Yue Chen, S. Gnanakaran, Bette Korber, Feng Gao. Emergence of SARS-CoV-2 through recombination and strong purifying selection. Science Advances, May 29, 2020: eabb9153 DOI: 10.1126/sciadv.abb9153

 Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Wednesday, 17 June 2020

How bacteria purge toxic metals



In E. coli bacterium, the inner membrane sensor protein CusS mobilizes from a clustered form upon sensing copper ions in the environment. CusS recruits the transcription regulator protein CusR and then breaks down ATP to phosphorylate CusR, which then proceeds to activate gene expression to help the cell defend against the toxic copper ions.

Cornell researchers combined genetic engineering, single-molecule tracking and protein quantitation to get a closer look at this mechanism and understand how it functions. The knowledge could lead to the development of more effective antibacterial treatments.

The bacteria's resistance is actually a tag-team operation, with two proteins working together inside the cell. One protein (CusS), in the inner membrane, senses the presence of the chemical or metal and sends a signal to a regulator protein (CusR) in the cytosol, or intercellular fluid. The regulator protein binds to DNA and activates a gene that generates transport proteins, which purge the toxin from the cell.

Microbiologists analyze these functions by using biochemical assays that remove the protein from the cell. However, that process prevents the scientists from observing the proteins in their native environment, and certain details, such as the spatial arrangement between proteins, have remained murky.


For a deeper analysis, researchers used single-cell imaging, whereby they tagged individual proteins in living E. coli with a fluorescent signal and imaged the proteins one at a time, tracking their motions. The procedure yielded millions of images and, ultimately, a finely detailed, qualitative map of the proteins' movement.

See:

Bing Fu, Kushal Sengupta, Lauren A. Genova, Ace George Santiago, Won Jung, Łukasz Krzemiński, Udit Kumar Chakraborty, Wenyao Zhang, Peng Chen. Metal-induced sensor mobilization turns on affinity to activate regulator for metal detoxification in live bacteria. Proceedings of the National Academy of Sciences, 2020; 201919816 DOI: 10.1073/pnas.1919816117

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Tuesday, 16 June 2020

Efficient biosolar cells modelled on nature



Potential sources of renewable energy include protein complexes that are responsible for photosynthesis. However, their efficiency in technical applications still leaves much to be desired. For example, they cannot convert green light into energy. A research team has successfully closed this so-called green gap by combining a photosynthesis protein complex with a light-collecting protein from cyanobacteria.

Biosolar cells are an innovative concept for converting sunlight into electrical energy. They are manufactured using biological components from nature. At their core are so-called photosystems: large protein complexes that are responsible for energy conversion in plants, algae and cyanobacteria. Photosystem II, PSII for short, plays a central role in the process, because it can use water as an electron source for the generation of electricity.


The researchers stabilised these super complexes using short-chain chemical crosslinkers that permanently fix the proteins at a very short distance from each other. In the next step, they inserted them into appropriate electrode structure.

This design enabled the researchers to use twice as many photons within the green gap, compared to a system without any light collection complexes.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Monday, 15 June 2020

Endotoxin control in depyrogenation tunnels



Understanding the way glassware is depyrogenated and how high concentrations of endotoxin can be used to assess how well depyrogenation tunnels are functioning is key to quality control.

In a new article, Tim Sandle explains:

Sandle, T. (2020) Endotoxin control in depyrogenation tunnels, Cleanroom Technology, February 2020. At: https://www.cleanroomtechnology.com/news/article_page/Endotoxin_control_in_depyrogenation_tunnels/162489

Here is an extract:


“The regulatory standard for validation of an endotoxin inactivation (depyrogenation) process is that it should be capable of reducing an endotoxin challenge through 3 log10 reduction. To ensure this limit works, it is required to clean materials before dry heat depyrogenation with WFI. Otherwise, at least in theory, you could have an item contaminated with 10,000 endotoxin units (EU) entering a validated endotoxin inactivation process and still emerging with 10 EU intact and ready to contaminate your product.

Dry heat depyrogenation is a complex process and is still poorly understood with contradictory research data. The phenomenon that complicates the picture is that inactivation may approximate to Second Order chemical kinetics with a high initial rate of inactivation, then tail off to nothing. In practice, this means that at any particular depyrogenating temperature you will get some degree of inactivation in some period of time or other, but beyond that point, you will get no further inactivation by holding the material at that temperature.”

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Sunday, 14 June 2020

Observing a continuous pathway to building blocks of life



A new study conducted by scientists at the Institute for Advanced Study, the Earth-Life Science Institute (ELSI), and the University of New South Wales marks an important step forward in the effort to understand the chemical origins of life. The findings of this study demonstrate how "continuous reaction networks" are capable of producing RNA precursors and possibly ultimately RNA itself -- a critical bridge to life.

While many of the mechanisms that propagate life are well understood, the transition from a prebiotic Earth to the era of biology remains shrouded in mystery. Previous experiments have demonstrated that simple organic compounds can be produced from the reactions of chemicals understood to exist in the primitive Earth environment. However, many of these experiments relied on coordinated experimenter interventions. This study goes further by employing a model that is minimally manipulated to most accurately simulate a natural environment.

To conduct this work, the team exposed a mixture of very simple small molecules -- common table salt, ammonia, phosphate, and hydrogen cyanide -- to a high energy gamma radiation source. These conditions simulate radioactive environments made possible by naturally occurring radioactive minerals, which were likely much more prevalent on early Earth. The team also allowed the reactions to intermittently dry out, simulating evaporation in shallow puddles and beaches. These experiments returned a variety of compounds that may have been important for the origins of life, including precursors to amino acids and other small compounds known to be useful for producing RNA.

The authors use the term "continuous reaction network" to describe an environment in which intermediates are not purified, side products are not removed, and no new reagents are added after the initial starting materials. In other words, the synthesis of molecules occurs in a dynamic environment in which widely varied compounds are continuously being formed and destroyed, and these products react with each other to form new compounds.


Future work will focus on mapping out reaction pathways for other chemical substances and testing whether further cycles of radiolysis followed by dry-down can generate higher order chemical products.

See:

Ruiqin Yi, Quoc Phuong Tran, Sarfaraz Ali, Isao Yoda, Zachary R. Adam, H. James Cleaves, Albert C. Fahrenbach. A continuous reaction network that produces RNA precursors. Proceedings of the National Academy of Sciences, 2020; 201922139 DOI: 10.1073/pnas.1922139117

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Saturday, 13 June 2020

Developing a new weapon in the war against superbugs




Australian microbiologists have shown that a newly discovered natural antibiotic, teixobactin, could be effective in treating bacterial lung conditions such as tuberculosis and those commonly associated with COVID-19. 
Teixobactin was discovered in 2015 by a team led by Professor Kim Lewis at Northeastern University in Boston in 2015. His company is now developing it as a human therapeutic.
The new University of Melbourne research is the first to explain how teixobactin works in relation to the superbug Staphylococcus aureus -- also known as MRSA.
MRSA is among bacteria responsible for several difficult-to-treat infections in humans, particularly post-viral secondary bacterial infections such as COVID-19 chest infections and influenza.


See:

Maytham Hussein, John A. Karas, Elena K. Schneider-Futschik, Fan Chen, James Swarbrick, Olivia K. A. Paulin, Daniel Hoyer, Mark Baker, Yan Zhu, Jian Li, Tony Velkov. The Killing Mechanism of Teixobactin against Methicillin-Resistant Staphylococcus aureus: an Untargeted Metabolomics Study. mSystems, 2020; 5 (3) DOI: 10.1128/mSystems.00077-20

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Friday, 12 June 2020

Digital PCR: Novel approach for COVID-19 testing



Stilla Technologies, a leading French provider of pioneering solutions for high precision genetic analysis, is offering a new high-throughput and cost-effective testing approach for COVID-19 by combining its digital PCR technology with the group testing

method and publishes the largest comparative study to date for group testing of SARS-CoV-2.

"We continue our efforts in the fight against Covid-19 and are proud today to present an innovative approach that greatly increases the testing capacity and meets the highest quality standards. This digital PCR based group testing method has a diagnostic sensitivity superior or equal to the current standard - that is individual RT-PCR testing - for group sizes up to 16 samples. The main benefit of this method is that it reduces the amount of reagent required to test a population by about 80% while reducing costs by as much and increasing test capacities by up to 10 times", said Rémi Dangla, Co-founder and CEO of Stilla Technologies.

Currently, testing for SARS-CoV-2 infections is central to strategies deployed to contain the spread of the virus worldwide. Patients are diagnosed predominantly using virological tests based on a technology called real-time reverse transcription polymerase chain reaction (RT-PCR).

RT-PCR technique is reaching its limits as the demand for SARS-CoV-2 RT-PCR testing is increasing worldwide as more countries are impacted by COVID-19. Firstly, because testing individual samples using RT-PCR is not scalable. Indeed, testing facilities are facing a scarcity of reagents worldwide while the demand reaches millions of tests. In fact, laboratories experienced a severe shortage of reagents at the start of the pandemic and are still under tension today to stock up on supplies. Secondly, because the cost of testing is not scalable to the world population. Group testing or sample pooling has been proposed as a solution to expand testing capabilities.

Test positivity rate for COVID-19 testing after lock-down (and before a pandemic) is usually below 10%, often around 1%, which means that 99 tests out of 100 are expected to yield negative results.

Group tests are optimal in such a configuration of low positivity rate. In a group test, the samples of 8, 16 or 32 individuals are combined into a pooled sample. This pooled sample is then tested. If the test is negative, it means that all the individuals in the group are negative. If it is positive, it means that at least one individual is a carrier of SARS-CoV-2. It is then necessary to test every sample separately again to identify the carrier(s). With a test positivity rate of 1%, only 1 in 10 groups will be positive. The test savings are therefore substantial, around 80%. Additionally, this group testing approach multiplies the number of individuals tested for a given amount of reagents by a factor of 5.

However, a risk associated with group tests is their sensitivity, which is deemed to be lower for large groups (n> 4). This reduction in sensitivity means that there is an increased risk of not detecting certain carriers of the virus with pooled tests compared to individual tests. This is where Stilla Technologies' Crystal digital PCR™ technology comes in. Digital PCR is known to be more sensitive than standard RT-PCR technology. Recent studies have verified it for the detection of SARS-CoV-2. Thus, the association of digital PCR with the group testing method would address the main problem of sensitivity.

This is what the study released today confirms. This study, conducted by the Virology Department of Bichat Hospital (AP-HP) in collaboration with CREST (Ecole Polytechnique) and Stilla Technologies is the largest comparative study carried out to date, systematically comparing group tests of SARS- CoV-2 to individual reference tests. It is also the first study to evaluate group tests combined with digital PCR.

Out of 448 samples tested, 26 and 25 tested positive by digital PCR group test, for group sizes of 8 and 16 samples. Against 25 tested positive with individual reference tests in RT-PCR. Thus, the study demonstrates a similar sensitivity to better for group tests by digital PCR, compared to individual tests by RT-PCR.

In conclusion, this new approach of group testing by digital PCR appears to have a diagnostic sensitivity "similar to better" compared to current tests in individual RT-PCR. However, this method makes it possible to reduce the amount of reagent required by up to 80% while reducing costs as well and increasing the capacity of testing by digital PCR up to 10 times. In conclusion, these are substantial advantages that make this approach a precious weapon to deploy in the fight against the pandemic.

Posted by Dr. Tim Sandle, 
Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Thursday, 11 June 2020

How your business can become more resilient during coronavirus

Many businesses have faced widespread disruption during the COVID-19 era, with many companies being forced to diversify or to advance digital transformation plans. Phillipa Hurrell provides some advice for business leaders.


According to Hurrell, these issues are inevitable, it is how you as a business have the ability to bounce back from any setbacks you are faced with. However, by following these five steps Hurrell says that business owners can deal with complications and to promptly come up with innovative plans to move their business forward.
Phillipa Hurrell is the Performance Coach of Hurrell Associates and The Courage Club. In conversation with Digital Journal, Phillipa looks into five ways focusing on increasing business owners' resilience and helping businesses grow, during these uncertain times.

Acceptance

Have you accepted the impact COVID-19 has had on your business and life? Acceptance is a simple concept; it means we understand that what has happened cannot be changed. Acceptance is important as it allows you to open up to new possibilities. You no longer put energy into fighting or questioning it. Instead, you put your energy into moving forward.

First, we must acknowledge what has happened. This cannot be rushed, it might take you a few hours, days or even weeks. We are human beings and, by our nature, emotional. It’s important at this phase to acknowledge the emotions you are feeling and be honest about them.

Write down how you are feeling, tell a trusted friend or family member. Sharing emotions is like a release valve that lets the pressure out. It’s one of the first steps in solving a problem. Emotions do not make you weak, they make you human and it’s a question of what we do about them and how long we choose to sit on them. Just be aware that the longer you choose to sit on the negative emotions, the more ingrained they become.

Ask yourself questions that can help you move out of this phase such as: is my current response appropriate and effective? Will it help my business? What can the business learn from this situation? What positives can I find in this situation?

Radical responsibility

Are you being 100% accountable for what you do next? When bad things happen in our lives the invitation is there to blame others and become bitter for our bad luck. It might be tempting to tell all that will listen of your unique bad luck in a certain situation. This stance is called learned helplessness and involves telling a story so often that you cannot do anything to help yourself but believe it.

The alternative perspective is to take full-blown responsibility for what you do next and what you choose to learn, what opportunities you choose to see and whether you choose to do something useful and positive. Our brains are amazing machines; they do what we instruct them to. Are you instructing your brain to find the possibilities and ideas to move you forward?

Positive mindset

Are you choosing a mindset that is going to help you? Our mindset is a way of thinking, a set of beliefs that govern how we feel and how we choose to react to situations. Your mindset has a huge impact on the course of your life. Is yours helping or hindering you? There are two particular mindsets that will help boost your resilience:

Focus on not merely surviving but thriving

Our lives are built on change; just think about how much change you have already successfully navigated in your life. From school to technology, moving house to changes in your family, friendships groups and illness and bereavement. You have so many examples of where you have been resilient and come through the change stronger.

Having a mindset fixed on your ability to not just survive during change but thrive, will help. Some businesses and people will come out of the current pandemic stronger, more customer-focused, streamlined and confident – so why shouldn’t you?

Gratitude

The second mindset is one of gratitude. If you are grateful for what you have, you will end up with more of it. Choosing every day to fix your mindset on what you have and what you are grateful for changes how your brain is wired and you very quickly start to notice all the amazing things that you have access to.

Focus on all that you have rather than what you lack. Spending one minute everyday writing down three things you are grateful for will help you think positively during these uncertain and worrying times.

Self-belief

Do you believe you can get through this? One of the biggest studies on the impact of self-belief was carried out by Albert Bandura and he found that a person’s self-belief is a significantly better predictor of future success than the actual results people have produced in the past.

So, what you have done in the past does not matter as much as how much you believe in yourself right now!

A good place to start in building self-belief is to notice all of the brilliant qualities you already possess. You are hugely valuable, you are unique, you are what has created your business and no one else has your specific set of skills, knowledge and capabilities.

Some people believe how valuable they are is based on their net worth or how big their business is and how many customers they have. Your value is ‘you’, you created all of those things. We forget where our success comes from and that we are capable of creating so much more.

Positive goals

Have you got clear, defined and inspiring goals? Goal setting is a simple way to help you feel like you are back in control.

Step one: Start by visualising what you want to happen.

Think about one year ahead (be positive and realistic) and allow your mind to create a vision of your future. How will you be feeling, what have you learned, how are you serving your customers? Having a clear purpose is really important for remaining resilient. Are your goals compelling? What could make these goals a 10 out of 10 for you?

Step two: Write down all the ways you could start to make these goals happen and all the options available to you.

Stretch your thinking beyond what you would normally consider. What could you do? What have others done in the past? The more you stretch your thinking, the better you will feel. It reinforces how many ways there are to look at any given situation or solve any problem, which stops you feeling stuck.

Step three: Choose the best options and start to research steps to move this forward.

Imagine if you took positive action every day to make these goals happen. Where would you be in six months? Information can empower you and it can stop you feeling stuck. A person with a smartphone now has more information, insight, and data at their fingertips than world leaders and the biggest companies did 15 years ago.

There is so much research and advice online to help you understand and act on the current climate. From what the experts believe the impacts will be (McKinsey & Company’s website has some interesting reading) to data on the changes in consumer habits in economies that are coming out of lockdown ahead of us.

Research how your specific industry is adapting and how other businesses are changing. What can you learn from the last recession and the companies that came out of that stronger? What can you learn about innovation, strategy, and helping your business pivot? And what can you learn from consumer forums? It’s about what proactive research you can do to gather insight that will help. Research, insight, and data helps but is all pointless if you don’t take action and learn.

And lastly, what we practice, we become, and most people have spent their lives telling themselves they can’t go after what they want, holding themselves back and playing it safe. Maybe it’s time to really think about what you want and have the courage to go after it!

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Wednesday, 10 June 2020

WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fourth report


The World Health Organisation has published ‘WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fourth report’.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

<a href="https://www.amazon.com/Acer-Display-Graphics-Keyboard-A515-43-R19L/dp/B07RF1XD36/ref=as_li_ss_il?s=electronics&ie=UTF8&qid=1590946236&sr=1-7&linkCode=li3&tag=pharmigpharma-20&linkId=ff3f39dcd18813a3b57b9f8ca1168bf2" target="_blank"><img border="0" src="//ws-na.amazon-adsystem.com/widgets/q?_encoding=UTF8&ASIN=B07RF1XD36&Format=_SL250_&ID=AsinImage&MarketPlace=US&ServiceVersion=20070822&WS=1&tag=pharmigpharma-20" ></a><img src="https://ir-na.amazon-adsystem.com/e/ir?t=pharmigpharma-20&l=li3&o=1&a=B07RF1XD36" width="1" height="1" border="0" alt="" style="border:none !important; margin:0px !important;" />

There is a new Annex 3 – ‘Production of water for injection by means other than distillation’.

An important section for microbiologists reads:

“The system should be monitored for its ongoing performance within defined parameters, including but not limited to, conductivity, total organic carbon (TOC) and microbial contamination.

A combination of online and offline monitoring of WFI should be done, to ensure that the appropriate water specification is maintained. TOC and conductivity should be monitored with online instruments. Use of rapid microbiological methods is encouraged for timely monitoring, and aids with rapid responses to prevent deterioration of the system.”


The report can be found here: https://www.who.int/publications-detail/978-92-4-000182-4

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Tuesday, 9 June 2020

Human Drug Compounding Outsourcing Facilities



The U.S. FDA has issued a new draft guidance document: “Current Good Manufacturing Practice—Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry.”


The guidance reflects further consideration of how CGMP requirements should be applied in light of the size and scope of an outsourcing facility's operations.

The document can be found here: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-guidance-human-drug-compounding-outsourcing-facilities-under

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Monday, 8 June 2020

Best practices for airflow visualization


Air is of fundamental importance to cleanrooms and clean air devices, either as a contamination source (microorganisms carried in the airstream) or as a control measure to minimise contamination (through the supply of clean air). Therefore, controlling a cleanroom requires careful attention to air filtration and airflow.

Assessing airflow is undertaken through airflow visualisation studies (or what are colloquially termed ‘smoke studies’). The purpose of flow visualisation is to confirm the smoothness, flow patterns and other spatial and temporal characteristics of airflow in an installation.

For this, the airflow is examined through airflow visualisation mapping whereby smoke is generated, and the behaviour of the smoke is studied and then captured by a video camera.

Air flow visualisation is one of the less clear-cut activities required of aseptic manufacturers. Regulations refer to such studies, yet little in the way of guidance is provided. However, judging by warning letters and other regulatory trends, many industries are running behind in terms of compliance expectations. The regulator findings suggest that evaluation, presentation and demonstration of airflow is not well understood. In this article, we will discuss the main regulatory findings, as evidenced from recent USA Food and Drug Administration (FDA) 483s and assess these for the main areas for concern and offer best practices for addressing the regulatory observations.


In relation to this topic, a new article of interest has been published in GMP Review. The reference is:

Saghee, M. R., Sandle, T., and Das, P. (2019) Regulatory inspections of sterile facilities – the focal points Part 2: Airflow visualisation, GMP Review, 18 (3): 15-21

For further details, please contact Tim Sandle.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Sunday, 7 June 2020

Cleaning validation Q&A



Recently Pharmig ran a session on cleaning validation. Here are some of the questions posed, together with the answers.


This is obviously not easy. If the surface area is smaller, then the count is still assessed as if it was 25cm2 (to indicate what a ‘norm’ is and to allow a comparison to be made). With other areas, all you can do is gain an approximate assessment in terms of the number and length of strokes. It is generally accepted that where a template cannot be used, the swabbing is approximate.

How can a swab template be used for the irregular surfaces? If not, what justification may be used?

A swab template cannot be used on an irregular surface, all you can do is gain an approximate assessment in terms of the number and length of strokes. It is generally accepted that where a template cannot be used, the swabbing is approximate.

Where you can, it is best to use a contact plate – it gives a better recovery and if there are cleaning residues present, the agar can contain an appropriate neutralisers.

Are there any regulations or guidelines for swabbing in this manner?

Not for microbiological swabbing. There are a number of good guidance texts, although these are not ‘standards’. The microbiological aspects are invariably overlooked, which was the reason for putting the webinar together.


How can training be provided for personnel to encompass this irregular swabbing?

Pharmig have run too training courses run by Gordon Farquharson in relation to this.

The best way is to use old items of equipment and allow personnel to practice on the lab bench, assessing their technique e.g. number of swab strokes, twisting the swab head etc.

Also when swabbing a surface do companies use cut out templates to get an accurate surface area? Or do companies just go on samplers judgement of surface area- between different samplers this could introduce a lot of variability?

Some companies use templates, which are sterilised. These will only work on relatively flat, regular shaped surfaces.

Others use judgement, and this has to be applied to irregular shaped surfaces. This can be supported by training.


As cannot contaminate equipment with organisms like can with chemicals. What does he think to the suggestion of supplementing cleaning validation study with lab based studies on samples of surfaces representative of the equipment? E.g. samples of SS 316L in lab – could contaminate with organism(s) representative of those found in facility and demonstrate effectiveness of cleaning regime/agents etc. is possible.  Overkill & unnecessary or good to do if have the time & resource?

This is useful if there is sufficient resource. The method outlined is similar to disinfectant efficacy testing in terms of phase 2 surface evaluation. However, it is not (as yet) a regulatory requirement. The standard approach is to evaluate ‘cleanliness’ through direct (swabbing) and indirect (rinse) samples.


The reference to facility isolates is interesting, although these are difficult to standardise.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Saturday, 6 June 2020

'Designer virus' is first new oral polio vaccine in 50 years


Phase 1 trial shows promise for completion of stalled eradication effort; offers lessons for COVID-19 vaccine development.

Virologists report promising Phase 1 clinical results for the first new oral polio vaccine in 50 years, which they have designed to be incapable of evolving the ability to cause disease in humans.

Before being halted due to the COVID-19 pandemic, a relentless vaccination campaign had nearly succeeded in eradicating polio from the world. Between 2000 and 2017, the World Health Organization (WHO) estimated that its campaign had reduced the burden of the disease by 99 percent, preventing more than 13 million children from becoming infected and risking potentially debilitating paralysis.

But in recent years, the eradication effort has been plagued by outbreaks of vaccine-derived polio -- in which the weakened virus used in oral polio vaccines evolved the ability to escape from vaccinated individuals and spread in communities with poor vaccination rates.
Now, with support from the Bill and Melinda Gates Foundation, UC San Francisco virologist Raul Andino, PhD and Andrew Macadam, PhD, of the UK's National Institute for Biological Standards and Control (NIBSC) report promising Phase 1 clinical results for the first new oral polio vaccine in 50 years, which they have designed to be incapable of evolving the ability to cause disease in humans.

In a 2017 study, Andino and colleagues discovered that in every vaccine-derived polio outbreak they studied, the virus had used the same three evolutionary steps to mutate from harmless vaccine into a regional menace.

In their new study, Andino, Macadam, and colleagues at the Gates Foundation, the Center for Vaccine Innovation and Access in Seattle, and the Centre for the Evaluation of Vaccination at the University of Antwerp have employed clever genetic wizardry based on decades of study of the poliovirus's biology to redesign the vaccine to ensure that is incapable of following this three-step pathway to re-evolve virulence. Specifically, they stabilized a region of the viral genome that is required for it to re-evolve the ability to infect humans, and ensured that the virus could not get rid of this modification even by exchanging genetic material with related viruses.


The trial found that the new designer polio vaccine was both more stable and more effective than the 50-year old Sabin vaccine from which it was derived. Specifically, the new vaccine caused participants to generate plentiful antibodies against the poliovirus, and despite shedding viral particles in their stool, those particles were unable to infect or cause paralysis in mice. In contrast, previous studies have found that when mice are exposed to viral samples shed by people vaccinated with the standard Sabin oral polio vaccine, as many as 90 percent develop paralysis.

See: Ming Te Yeh, Erika Bujaki, Patrick T. Dolan, Matthew Smith, Rahnuma Wahid, John Konz, Amy J. Weiner, Ananda S. Bandyopadhyay, Pierre Van Damme, Ilse De Coster, Hilde Revets, Andrew Macadam, Raul Andino. Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host & Microbe, 2020; DOI: 10.1016/j.chom.2020.04.003

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Special offers